[Therapeutic strategy in myeloblastic syndromes].
The treatment of myelodysplastic syndromes (MDSs) continues to be challenging and difficult to standardize. This article describes a decision tree for the treatment of MDSs based on age, presence or absence of a potential HLA-identical donor, and prognostic factors including bone marrow blast proportion, severity of cytopenias, and karyotype.
Fenaux
P
P
Service des Maladies du Sang, CHRU, Lille, France.
D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000276:immunology / Q000628:therapy*; D014184:Transplantation, Homologous
D006680:HLA Antigens